IMR Press / EJGO / Volume 21 / Issue 4 / pii/2000183

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Distinguished Expert Series

Estrogen replacement therapy and ovarian cancer

Show Less
1 Department of Internal Medicine Specialties, Section of Gynecologic and Medical Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
2 Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Eur. J. Gynaecol. Oncol. 2000, 21(4), 348–354;
Published: 10 August 2000
Abstract

Estrogen replacement therapy (ERT) has been shown to be of benefit for menopausal women, especially in prevention of coronary heart disease and osteoporotic fractures. Cancer fear is an important obstacle to use of ERT. From our literature review, there is a weak or no association between ERT and ovarian cancer risk. Individual risk of cancer should be considered before ERT use. The second issue in this review is ERT in patients with ovarian cancer. The majority of patients with ovarian cancer are postmenopausal or beco­me menopausal after surgery. ERT is considered by many physicians to be contraindicated in patients with cancer. However, there is evidence that ERT in selected cancer patients may be of benefit for survival and quality of life. After weighing the evidence from stu­dies on ERT in patients with ovarian, breast or endometrial cancer, we propose the use of ERT in selected ovarian cancer patients who are suffering from or are at a high risk of debilitating menopausal symptoms, osteoporosis, and coronary heart disease. The benefit of ERT to selected patient's health and quality of life appears to outweigh the risk of cancer recurrence.

Keywords
Estrogen replacement therapy (ERT)
Ovarian cancer risk
Survival
Quality of life
Ovarian cancer
Risk of ovarian cancer recurrence
Share
Back to top